CD276 and neoplasm: The clinical efficacy of this approach was recently shown in a phase I/II trial for HNSCC [NCT02475213] and NSCLC patients [44], where the combination of B7-H3 and PD-1 blockade was shown to be a safe and effective anti-tumour treatment option.